News About: Pharm. Industry
Pharma industry sensitive over ‘secret survey for rebates’
The Korea Pharmaceutical and Bio-Pharma Manufacturers Association will hold a board meeting on the 17th.
The board meeting is the first meeting after the appointment of Chairman Hee-Mok Won since the last board meeti...
Drug price negotiation for lung cancer treatment ‘Tagrisso’ failed
The drug price negotiation of ‘Tagrisso,’ a new lung cancer drug of AstraZeneca, a multinational pharmaceutical company, was delayed for a week due to the Ministry of Health and Welfare’s order to suspend negotiation,...
Abott’s new partner for digestive disorder treatment, ‘Green Cross’
Abott and Green Cross have attracted the industry as establishing a common front in the Korean digestive disorder treatment market.
‘Ganaton Tab’ Abott Korea has directly sold after acquiring its license from a Korea...
Korean pharma industry encroach by multinational companies, only 23% of them were pure Korean medicines
Despite the government’s pharmaceutical industry nurturing policy, major value-added medicine markets in Korea have been encroached by multinational pharmaceutical companies.
According to the materials that the Healt...
SK Chemicals divided into investment & business parts
SK Chemicals will hold an extraordinary general meeting at SK Chemicals Building losed in Bundang-gu, Seongnam-si at 9am on the 27th of October and discuss about the ‘holding company management’ plan which will divide...
Rebates were increased instead? Needing special measures for this
Despite pharmaceutical companies’ efforts of eradicating rebates through ethical business management, the number of illegal rebate offenders were increasing for the past 3 years and there have been still reportedly a ...
Daewoong Pharmaceutical acquires sale right and license of Sandoz’s osteoporosis treatmentDaewoong Pharmaceutical(CEO Jong-Wook Lee) announce the company acquired a Korean sale right and license of ‘Zoledronic Acid Inj 5mg/100ml,’ a osteoporosis treatment, from Novar...
|
Yuhan Corporation & Samsung Bioepis sign exclusive biosimilar sales agreement
Yuhan Corporation(CEO Jung-Hee Lee) signed an exclusive sales agreement of the Remicade(generic name: infliximab) biosimilar(SB2) and the Enbrel(generic name: etanercept) biosimilar(SB4) in Korea with Samsung Bioepis(...
Lilly’s Trulicity applied for national health insurance benefit in combination with insulin
Lilly Korea(CEO Paul Henry Huibers) announced the Ministry of Health and Welfare’s national health insurance benefit standards were extensively revised under a revision bill for ‘Trulicity(generic name: dulaglutide)’ ...
Illegal rebate offenders increased 11 times more
Illegal drug rebates have been active again for the past 3 years as there are 11 times more illegal acts of providing illegal rebates and the amount of illegal bribery got double.
According to a report the Ministry o...
